Zhen Su, CEO and Entrepreneur at Marengo Therapeutics, shared a post on LinkedIn:
“It is a journey — and it truly takes a village!
Returning home from SITC filled with gratitude and appreciation for all the START-001 investigators and teammates who share the passion and conviction to unleash the full potential of the T cell Vβ repertoire — activating the patient’s own immune system to fight cancer.
A special thanks to Dr. Aurélien Marabelle for delivering a stellar plenary presentation and sharing our clinical findings as a Late-Breaking Abstract at the 40th SITC Annual Meeting.
A simple yet powerful approach to a complex challenge — overcoming PD-1–resistant cancers by reinvigorating the patient’s own T cells and empowering them to fight malignant cells.
Thank you Society for Immunotherapy of Cancer (SITC) for the opportunity to share our findings at 40th anniversary.
Let’s go Marengo Therapeutics.”
More posts featuring Zhen Su.
